Dr.ย Sang-Weย Kim
MD, Professor of Oncology
Professor, Division of Oncology
corporate_fareAsan Medical Center, Seoul
Sang-We Kim
MD, Professor of Oncology
Prof. Sang-We Kim is a senior medical oncologist and Professor in the Division of Oncology at Asan Medical Center, Seoul, one of South Korea's foremost tertiary cancer centres. His clinical and academic work centres on lung cancer โ particularly non-small cell lung cancer โ with a strong emphasis on molecularly targeted therapy, immunotherapy, and next-generation sequencing-guided treatment selection.
Prof. Kim's research spans EGFR-mutated and HER2-mutant NSCLC, EGFR exon 20 insertion-positive lung cancer, antibody-drug conjugates, and precision oncology approaches supported by Asan Medical Center's Centre for Precision Cancer Medicine. His academic contributions have been recognised by Clarivate, which listed him among its Highly Cited Researchers in Clinical Medicine for three consecutive years โ first in the Cross-Field category in 2023, then in Clinical Medicine in both 2024 and 2025. He is affiliated with the University of Ulsan College of Medicine and has contributed to landmark international clinical trials and peer-reviewed publications in journals including the Journal of Clinical Oncology and JAMA Oncology.
Asan Medical Center's International Healthcare Centre supports overseas patients with appointment coordination, interpretation services, medical record review, and second-opinion consultations. CancerFax can help coordinate your case submission and follow-up support.
Why Consider Prof. Sang-We Kim?
Prof. Sang-We Kim combines one of Korea's most active lung cancer research profiles with clinical expertise in the molecular and targeted treatment of advanced NSCLC at Asan Medical Center, a globally recognised oncology centre in Seoul.
Areas of Specialisation
Advanced lung cancer treatment with a focus on molecular profiling and precision oncology
Prof. Sang-We Kim's practice is centred on advanced non-small cell lung cancer, with particular depth in molecularly driven disease. His work covers EGFR- and HER2-targeted treatment, exon 20 insertion-positive NSCLC, next-generation sequencing, immunotherapy, and novel systemic approaches including antibody-drug conjugates.
Lung Cancer Targeted Therapy
Molecularly guided treatment selection for patients with actionable driver mutations in NSCLC.
- arrow_rightEGFR tyrosine kinase inhibitor selection based on mutation type and treatment history
- arrow_rightOsimertinib-based treatment research, including resistance assessment
- arrow_rightEGFR exon 20 insertion-positive metastatic NSCLC management
- arrow_rightEGFR T790M-positive disease evaluation and subsequent therapy planning
- arrow_rightHER2-directed systemic therapy for eligible lung cancer patients
- arrow_rightAntibody-drug conjugate research, including trastuzumab deruxtecan in HER2-mutant NSCLC
- arrow_rightBiomarker-guided patient selection for HER2-targeted approaches
Precision Oncology & Immunotherapy
Genomics-informed treatment planning and systemic immunotherapy for advanced NSCLC.
- arrow_rightComprehensive NGS panel-based identification of actionable alterations in lung adenocarcinoma
- arrow_rightMolecular tumour board review through Asan Medical Center's Centre for Precision Cancer Medicine
- arrow_rightTreatment sequencing informed by genetic profiling and resistance mutation analysis
- arrow_rightImmunotherapy planning for NSCLC patients with appropriate biomarker profiles
- arrow_rightPD-1 and PD-L1 inhibitor approaches for advanced lung cancer
- arrow_rightResearch contributions in immunotherapy combinations for metastatic NSCLC
Procedures Performed
Systemic treatment, molecular profiling, and clinical services for advanced lung cancer
Prof. Sang-We Kim's clinical services cover the full spectrum of systemic oncology for advanced NSCLC โ from initial molecular profiling and treatment planning to targeted therapy administration, immunotherapy, antibody-drug conjugate protocols, and specialist second-opinion review.
Systemic Lung Cancer Treatment
Medical OncologyChemotherapy and combination systemic protocols for advanced or metastatic NSCLC.
EGFR & HER2-Directed Targeted Therapy
Targeted TherapyMolecularly guided targeted treatment selection for NSCLC patients with driver mutations.
Molecular & Genomic Profiling
DiagnosisComprehensive molecular evaluation to identify actionable alterations and personalise treatment planning.
Expert Second Opinion โ Lung Cancer
Second OpinionIndependent specialist review of advanced NSCLC cases submitted through CancerFax or Asan Medical Center's international consultation service.
Research & Publications
Clarivate Highly Cited Researcher with contributions to landmark NSCLC trials and peer-reviewed journals
Prof. Sang-We Kim has an established publication record in thoracic oncology and precision cancer medicine. His research themes include EGFR-mutated and HER2-mutant NSCLC, EGFR exon 20 insertion-positive disease, antibody-drug conjugates, immunotherapy, and NGS-guided treatment selection in lung adenocarcinoma.
Prof. Kim's three consecutive Clarivate Highly Cited Researcher designations reflect a publication record with measurable global impact in lung cancer research. A more complete publication list is available through PubMed and Google Scholar.
Education & Training
Prof. Sang-We Kim holds a medical qualification and is a senior academic faculty member at Asan Medical Center, affiliated with the University of Ulsan College of Medicine. Detailed education and training information has not been confirmed from publicly reviewed sources and will be verified directly with the institution prior to publication.
Clinical Experience
Prof. Sang-We Kim is a long-standing member of the Division of Oncology at Asan Medical Center, Seoul, one of South Korea's foremost tertiary cancer institutions, and holds academic affiliation with the University of Ulsan College of Medicine. His career has centred on the clinical management and clinical research of advanced lung cancer.
Languages & International
The consultation language preference of Prof. Sang-We Kim has not been independently verified from public sources. Asan Medical Center's International Healthcare Centre provides professional interpretation services for international patients.
Asan Medical Center's International Healthcare Centre provides professional interpretation services for overseas patients. CancerFax can coordinate case submission and interpreter arrangements in advance of consultation.
Asan Medical Center provides interpretation support in English, Chinese, Japanese, Russian, Arabic, Mongolian, and additional languages through its international patient programme.
How CancerFax Helps You Access Dr. Sang-We Kim
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Sang-We Kim's team โ with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history โ prepared as a structured clinical summary for Dr. Sang-We Kim's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Sang-We Kim before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Sang-We Kim's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Sang-We Kim's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Sang-We Kim's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Prof. Sang-We Kim
Prof. Sang-We Kim specialises in lung cancer, particularly non-small cell lung cancer (NSCLC). His clinical and research focus includes EGFR-mutated NSCLC, HER2-mutant metastatic NSCLC, EGFR exon 20 insertion-positive NSCLC, and lung adenocarcinoma with actionable genetic alterations requiring molecular-guided treatment planning.
Asan Medical Center's International Healthcare Centre supports overseas patients with appointment coordination, interpretation services, medical documentation, and treatment coordination. CancerFax can help prepare and submit your medical records for review and coordinate the consultation process with the hospital, subject to availability and case acceptance.
Submit your medical reports through CancerFax using the 'Send Your Reports' button. The CancerFax team will review your documents, prepare a structured oncology summary, and coordinate the next steps with Asan Medical Center. Asan Medical Center also offers written second opinions for overseas patients based on submitted pathology reports, imaging, and test results.
Prof. Kim's research and clinical work covers EGFR tyrosine kinase inhibitors (including osimertinib and gefitinib), HER2-directed antibody-drug conjugates such as trastuzumab deruxtecan, and mobocertinib for EGFR exon 20 insertion-positive NSCLC. He works within Asan Medical Center's Centre for Precision Cancer Medicine, which uses molecular tumour board review to guide personalised treatment selection.
Prof. Kim has participated in multiple international clinical trials, including the DESTINY-Lung02 study of trastuzumab deruxtecan in HER2-mutant metastatic NSCLC and the mobocertinib Phase 1/2 trial in EGFR exon 20 insertion-positive metastatic NSCLC. He has also been listed as a responsible party on registered Asan Medical Center trials on ClinicalTrials.gov. CancerFax can provide information on open trial eligibility where relevant to your case.
Asan Medical Center reported that Prof. Kim was named a Clarivate Highly Cited Researcher for three consecutive years โ in the Cross-Field category in 2023, and in the Clinical Medicine category in 2024 and 2025. This designation places him among the top 1% of researchers globally by citation impact. His publication record includes contributions to the Journal of Clinical Oncology and JAMA Oncology on landmark NSCLC trials.
Connect with Sang-We Kim Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.